GI Dynamics presents EndoBarrier research

GI Dynamics (ASX:GID) has published more scientific data supporting the ability of its EndoBarrier Therapy to improve glycaemic control and reduce the reliance on medication in patients with obesity and type 2 diabetes.

Findings from a series of studies and analyses were presented at the 74th Scientific Sessions of the American Diabetes Association in San Francisco last week.

The data build on evidence supporting the ability of EndoBarrier to positively impact HbA1c - a measure of blood glucose levels - and reduce weight in obese type 2 diabetics.

They also show that EndoBarrier can potentially reduce reliance on diabetes medications including insulin therapy.

During one study in 33 patients, EndoBarrier resulted in a 29% reduction in average daily glucose within days post-implantation, even as the patients’ insulin dose was reduced by 50%.

The poster presentations also include more details of the potential mechanism of action behind the treatment.

During a trial in seven patients, primary and secondary bile acid levels were measured pre-implantation and following removal at 52 weeks of treatment. EndoBarrier caused a statistically significant increase in total fasting bile acids. This mechanism is reminiscent of the effects of gastric bypass surgery.

EndoBarrier is a flexible, removable tube-shaped liner designed to be inserted endoscopically, and serve as a temporary barrier between food and a portion of the intestinal wall.

GI Dynamics (ASX:GID) shares were trading 0.86% lower at $0.575 as of around 1.30 pm on Monday.